Previous 10 | Next 10 |
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), will host a conference call on November 9, 2020 at ...
Infinity Pharmaceuticals (INFI) shares jumped 19% in premarket, in reaction to FDA's Fast Track review tag for its eganelisib (IPI-549) in combination with a checkpoint inhibitor and chemotherapy, for the treatment of inoperable locally advanced or metastatic triple-negative breast ...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganelisib (IPI-549) in combination with a checkpoint inhibitor and chemotherapy for the treatment of patients with inoperable locall...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that management will be partici...
Should These Penny Stocks Join Your “Buy” or “Sell” List? Penny stocks have been on fire this year with breakouts going into the 1,000s of percentage points. This used to be somewhat infrequent and when we would see such a move, it typically came from a thinly tra...
Infinity Pharmaceuticals, Inc. (INFI) Q2 2020 Earnings Conference Call July 30, 2020 4:30 PM ET Company Participants Jayne Kauffman – Investor Relations Adelene Perkins – Chief Executive Officer Larry Bloch – President Brian Schwartz – Consulting Chi...
Infinity Pharmaceuticals (NASDAQ: INFI ) : Q2 GAAP EPS of -$0.16 beats by $0.04 . Revenue of $0.36M (+38.5% Y/Y) beats by $0.16M . Shares -1.2% . Press Release More news on: Infinity Pharmaceuticals, Inc., Earnings news and commentary, Consumer stocks news, ,
– MARIO-275 Dose Reduction Effective in Reducing Liver Enzyme Elevations. Interim Efficacy Analysis Expected by Year End. – – Encouraging Early Clinical Activity in MARIO-3 Front-Line Triple Negative Breast Cancer Cohort to be Presented by Year End – ...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on July 30, 2020 at 4:30 p.m. ET to review its second quarter 2020 financial results and provide an update on the company. A live webcast of the conference call can be accessed in the Investors/Media section of In...
Document Security Systems (NYSEMKT: DSS ) +69% after its target acquisition Company, Impact Biomedical reports positive results of equivir and linebacker for treatment of COVID-19. More news on: Document Security Systems, Inc., Infinity Pharmaceuticals, Inc., Dolphin Entertainment...
News, Short Squeeze, Breakout and More Instantly...
Infinity Pharmaceuticals Inc. Company Name:
INFI Stock Symbol:
NASDAQ Market:
Infinity Pharmaceuticals Inc. Website:
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - Infinitum Copper Corp. (TSXV: INFI) (OTCQB: INUMF) (" Infinitum " or the " Company ") is pleased to announce that it has received acceptance from the TSX Venture Exchange (the " Exchange ") of the previously announced consolidation ...
VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Infinitum Copper Corp. (TSXV:INFI, OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce the details of a proposed consolidation of its common shares. On March 21, 2024, in accordance with the constating documents of the Company, the ...
VANCOUVER, BC / ACCESSWIRE / March 6, 2024 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company "). Further to the Company's news release of March 5, 2024 (the " March 5, 2024 News Release "), this is to advise that the Company has amended the terms of its private pl...